Jane Street Group LLC Decreases Stock Holdings in OmniAb, Inc. (NASDAQ:OABI)

Jane Street Group LLC decreased its holdings in shares of OmniAb, Inc. (NASDAQ:OABI) by 21.2% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 136,359 shares of the company’s stock after selling 36,694 shares during the period. Jane Street Group LLC’s holdings in OmniAb were worth $577,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. CWC Advisors LLC. purchased a new position in OmniAb in the 3rd quarter valued at $54,000. Walleye Capital LLC purchased a new position in OmniAb in the 3rd quarter valued at $61,000. Intech Investment Management LLC purchased a new position in OmniAb in the 3rd quarter valued at $70,000. China Universal Asset Management Co. Ltd. lifted its holdings in OmniAb by 64.5% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 22,727 shares of the company’s stock valued at $96,000 after purchasing an additional 8,909 shares in the last quarter. Finally, Palumbo Wealth Management LLC lifted its holdings in OmniAb by 12.5% in the 3rd quarter. Palumbo Wealth Management LLC now owns 24,640 shares of the company’s stock valued at $104,000 after purchasing an additional 2,744 shares in the last quarter. Hedge funds and other institutional investors own 72.08% of the company’s stock.

OmniAb Stock Up 5.1 %

NASDAQ OABI opened at $3.68 on Friday. OmniAb, Inc. has a 52 week low of $3.43 and a 52 week high of $6.72. The business’s fifty day simple moving average is $3.92 and its 200-day simple moving average is $4.11. The firm has a market cap of $519.67 million, a PE ratio of -5.94 and a beta of -0.10.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on the company. Benchmark restated a “buy” rating and issued a $8.00 price objective on shares of OmniAb in a report on Thursday, November 14th. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of OmniAb in a report on Thursday, November 14th.

OmniAb Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.